BHRC BLOG
Best Peptides for Weight Loss (2026)
Peptide Therapy
Not all weight loss protocols are created equal — and not all peptides work the same way. If you’ve been researching peptide therapy for weight loss, you’ve likely found a flood of conflicting information about semaglutide, tirzepatide, tesamorelin, CJC-1295, and a dozen others. This guide cuts through the noise.
At Beverly Hills Rejuvenation Center, our physicians oversee peptide protocols across 22 locations nationally. Here’s an honest breakdown of the best peptides for weight loss in 2026 — what the research actually shows, who each one is appropriate for, and how BHRC protocols are designed to maximize results safely.
How Peptides Affect Weight Loss
Peptides influence weight through several distinct mechanisms, which is why “the best peptide for weight loss” depends entirely on what’s driving your weight gain in the first place.
Mechanism 01
GLP-1 Receptor Agonism
Slows gastric emptying, reduces appetite signaling in the hypothalamus, and regulates blood sugar — producing the powerful satiety effect seen with semaglutide and tirzepatide.
Mechanism 02
Growth Hormone Stimulation
Peptides like CJC-1295 and Ipamorelin stimulate the pituitary to release growth hormone, which mobilizes stored fat as fuel and helps preserve lean muscle during caloric restriction.
Mechanism 03
Direct Lipolytic Action
AOD-9604 — a fragment of human growth hormone — directly activates lipolysis (fat breakdown) without affecting blood sugar or IGF-1, making it relevant for patients who can’t use full GH therapy.
Mechanism 04
Visceral Fat Reduction
Tesamorelin, a GHRH analogue, is FDA-approved for visceral fat reduction and has been studied in non-HIV populations for its ability to reduce deep abdominal fat — the metabolically dangerous kind.
The 5 Best Peptides for Weight Loss (2026)
1. Semaglutide — The Gold Standard for Significant Weight Loss
Semaglutide (brand names Wegovy and Ozempic) is a GLP-1 receptor agonist originally developed for type 2 diabetes that demonstrated remarkable weight loss in metabolically healthy adults. The landmark STEP-1 trial showed an average of 14.9% body weight reduction over 68 weeks in non-diabetic adults with obesity — roughly 2–3x what was previously achievable with any pharmaceutical.
The SELECT trial (2023) further established semaglutide’s cardiovascular benefits, showing a 20% reduction in major adverse cardiovascular events in overweight adults with established heart disease — even without diabetes.
Best for: Adults with 15–50+ lbs to lose, especially those with metabolic syndrome, insulin resistance, or cardiovascular risk factors.
2. Tirzepatide — The Strongest GLP-1 Option Available
Tirzepatide (Zepbound / Mounjaro) targets both GLP-1 and GIP receptors simultaneously — a “dual agonist” mechanism that makes it the most powerful weight loss medication currently available. The SURMOUNT-1 trial produced a jaw-dropping average of 22.5% body weight loss at the highest dose (15mg) over 72 weeks.
Best for: Patients with significant weight to lose who want the maximum effective dose available, particularly those who haven’t responded optimally to semaglutide.
3. Tesamorelin — Targeted Visceral Fat Reduction
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates the pituitary to produce growth hormone in a natural, pulsatile pattern. It was originally FDA-approved to reduce visceral fat accumulation in HIV patients on antiretroviral therapy, but it’s increasingly used off-label in metabolically healthy adults with excess abdominal fat.
Studies show tesamorelin reduces visceral adipose tissue (VAT) by 15–18% over 26–52 weeks while improving IGF-1 levels, lipid profiles, and body composition. Unlike full GH injections, tesamorelin preserves the body’s natural feedback loops and avoids the side effect profile of exogenous GH.
Best for: Adults with excess visceral (abdominal) fat, metabolic syndrome, or those who don’t qualify for GLP-1 therapy. Often used in combination with other peptides.
4. CJC-1295 / Ipamorelin Stack — Body Recomposition + Fat Loss
CJC-1295 is a GHRH analogue, and Ipamorelin is a selective growth hormone secretagogue. Used together, they create a synergistic increase in growth hormone output — CJC-1295 raises the amplitude of GH pulses while Ipamorelin increases their frequency. The result is enhanced fat mobilization, improved muscle preservation, better sleep quality (GH is primarily released during slow-wave sleep), and improved recovery.
This combination doesn’t produce the dramatic scale-based weight loss seen with GLP-1 agents, but it is highly effective for body recomposition — losing fat while gaining or preserving lean muscle. It’s a favorite protocol for patients who are already at a healthy weight but want to reduce body fat percentage and improve how they look and feel.
Best for: Patients with 5–20 lbs to lose, athletes, patients focused on body composition rather than scale weight, or those combining with GLP-1 therapy to preserve muscle during rapid weight loss.
5. AOD-9604 — The Lipolytic Fragment
AOD-9604 is derived from the C-terminal fragment of human growth hormone (residues 177–191). It retains the fat-burning properties of HGH without affecting blood sugar, IGF-1 levels, or insulin sensitivity — making it a safer option for patients who want lipolytic benefits but have concerns about growth hormone’s metabolic effects.
Clinical evidence for AOD-9604 is more limited than the GLP-1 agents, but it has a favorable safety profile and is often added to existing protocols as a targeted lipolytic agent — particularly for stubborn fat deposits.
Best for: Patients on existing protocols who want to target stubborn fat, or those who can’t use GLP-1 therapy and want a lipolytic peptide with minimal systemic effects.
Side-by-Side Comparison
| Peptide | Mechanism | Avg. Weight Loss | Best For | Rx Required |
|---|---|---|---|---|
| Semaglutide | GLP-1 agonist | ~14.9% STEP-1 | Significant weight loss, metabolic health | Yes |
| Tirzepatide | GLP-1 + GIP dual agonist | ~22.5% SURMOUNT-1 | Maximum weight loss, non-sema responders | Yes |
| Tesamorelin | GHRH analogue | 15–18% visceral fat reduction | Abdominal fat, metabolic syndrome | Yes |
| CJC-1295 / Ipamorelin | GH secretagogues | Body recomposition | Fat + muscle, athletes, maintenance | Yes (compounded) |
| AOD-9604 | GH fragment (lipolytic) | Targeted fat reduction | Stubborn fat, add-on to existing protocol | Yes (compounded) |
How BHRC Approaches Weight Loss Peptide Protocols
Weight loss peptide therapy at BHRC begins with a comprehensive consultation — not a prescription. Before any protocol is designed, our physicians review your:
- Complete health history and current medications
- Metabolic labs: fasting glucose, HbA1c, insulin, thyroid, lipid panel, CMP
- Body composition analysis (not just scale weight)
- Weight history and prior attempts at weight management
- Cardiovascular risk factors
- Goals — total weight loss, body composition, or metabolic health optimization
Most patients start on a conservative titration schedule — doses increase gradually over 8–12 weeks to minimize GI side effects. We monitor labs at 3 and 6 months to assess response and adjust protocols as needed. For patients on GLP-1 therapy who want to preserve lean muscle, we often layer in a CJC-1295/Ipamorelin stack.
Consultations are available in person or virtually at any of our 22 locations.
Start Your Journey
Find the Right Weight Loss
Peptide for You
A 30-minute consultation with a BHRC physician is the first step. We’ll review your labs, goals, and health history to design a protocol that’s right for you — in person or virtually.
Book a Free ConsultationPeptide Therapy Locations Near You
BHRC offers peptide weight loss consultations at all six of our primary locations, with virtual consultations available nationwide.
West Hollywood
California
West Los Angeles
California
Paradise Valley
Arizona
Westlake Village
California
Valencia
California
Summerlin
Nevada
Frequently Asked Questions
What are the best peptides for weight loss?
The most clinically studied options in 2026 are semaglutide and tirzepatide (GLP-1 agents), tesamorelin (visceral fat reduction), and the CJC-1295/Ipamorelin stack (body recomposition). The right choice depends on your goals and health profile.
How much weight can you lose with peptides?
Semaglutide produced an average 14.9% body weight loss in STEP-1; tirzepatide produced up to 22.5% in SURMOUNT-1. Tesamorelin reduces visceral fat 15–18%. GH peptide stacks are body recomposition tools — the “weight lost” may be modest but body fat percentage changes significantly.
Are weight loss peptides safe?
FDA-approved peptides like semaglutide and tirzepatide have extensive clinical safety data. Compounded peptides are used under physician supervision at BHRC with baseline labs and monitoring protocols in place.
What is the difference between semaglutide and tirzepatide?
Semaglutide targets GLP-1 receptors only; tirzepatide is a dual GLP-1/GIP agonist with stronger average results. Tirzepatide is typically used when patients need more aggressive weight loss or haven’t responded fully to semaglutide.
Can you combine peptides for weight loss?
Yes. BHRC providers commonly combine a GLP-1 agent with a GH peptide stack to simultaneously drive fat loss and preserve lean muscle. BPC-157 is sometimes added to support gut health and reduce GI side effects.
Do you need a prescription for weight loss peptides?
Yes. All weight loss peptides — including semaglutide, tirzepatide, tesamorelin, and compounded peptide stacks — require a physician prescription in the US.
How long does it take to see results?
GLP-1 patients typically notice appetite reduction within 1–2 weeks and measurable weight loss by weeks 4–8. Peak results in clinical trials occurred at 68–72 weeks. GH peptide stacks show meaningful body recomposition results over 3–6 months.
Is peptide therapy for weight loss covered by insurance?
Branded GLP-1 medications may be covered depending on diagnosis and plan. Compounded peptides and other protocols are typically self-pay. Your BHRC provider will review all options during your consultation.
1. Wilding JPH et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” NEJM, 2021. STEP-1 trial.
2. Jastreboff AM et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” NEJM, 2022. SURMOUNT-1 trial.
3. Falutz J et al. “Metabolic effects of a growth hormone–releasing factor in patients with HIV.” NEJM, 2007. Tesamorelin VAT reduction.
4. Lincoff AM et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” NEJM, 2023. SELECT trial.
